<DOC>
	<DOCNO>NCT00728468</DOCNO>
	<brief_summary>Research test tube suggest may affect cytochrome P450 2D6 ( CYP2D6 ) , important enzyme responsible eliminate many drug cancer patient need take , include dextromethorphan . The purpose study test impact PF-00299804 activity CYP2D6 , human body handle dextromethorphan .</brief_summary>
	<brief_title>A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients</brief_title>
	<detailed_description>To assess effect repeat dose 45 mg QD PF-00299804 pharmacokinetics dextromethorphan , CYP2D6 probe , cancer patient advance malignant solid tumor .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<criteria>Patients histologically cytologically confirm advanced malignant solid tumor currently approve treatment unresponsive currently approve therapy ; Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Patients performance status 2 could eligible upon agreement sponsor investigator ; Adequate bone marrow , renal , liver cardiac function ; History Interstitial Lung Disease ( ILD ) . Drugs known CYP2D6 inhibitory effect Drugs highly dependent CYP2D6 metabolism . Women pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>PF-00299804</keyword>
	<keyword>Dextromethorphan</keyword>
	<keyword>CYP2D6 Inhibition</keyword>
	<keyword>Cancer Patients</keyword>
</DOC>